List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Antibody-drug conjugates (ADCs) are emerging as a breakthrough in the fight against gynaecological cancers, offering targeted treatment for cervical, ovarian and uterine tumours.
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
A thyroid hormone receptor may play a key role in prostate cancer growth, offering a potential new target for treating aggressive forms of the disease.
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer cells spreading to lymph nodes depend on a protein called FSP1 to avoid cell death.
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows tumour growth.
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
Scientists have discovered that two existing pain medications – bupivacaine and rimegepant – may not only relieve the severe pain caused by osteosarcoma but also slow the disease’s growth.
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
A new study has revealed that the enzyme EZH2 triggers abnormal cell division that fuels metastasis, and blocking this enzyme with existing drugs could restore normal cell behaviour to stop cancer from spreading.
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
A newly discovered RNA molecule, EUDAL, helps oral cancers survive chemotherapy by keeping a key growth protein permanently active. Researchers say targeting EUDAL could predict resistance and improve treatment outcomes.
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
